The following outcomes were eligible for meta-analysis: mortality in 4 trials13–15,27; length of hospital stay in 5 trials13–15,28,29; multiple organ dysfunction syndrome in 3 trials13,14,27; acute respiratory distress syndrome in 3 trials13,15,30; acute kidney injury in 3 trials13,15,30; shock in 3 trials13,15,30; symptom reduction in 6 trials13–15,28,29,31; and abdominal pain relief in 5 trials13–15,28,30; CRP change in 6 trials13,15,28–30,32. This evidence concerns the gene CRP and acute kidney injury.